Approximately 40% of patients with terminal illnesses report significant distress at the end of life.

Palliative & End-of-Life Distress

Palliative and end-of-life distress represents a significant psychosocial challenge faced by patients with life-limiting illnesses, significantly impacting quality of life. Recent research suggests that psychedelic compounds, particularly psilocybin, may offer promising therapeutic benefits in alleviating existential distress and improving psychological well-being in these patients.

What is Palliative & End-of-Life Distress?

Palliative and end-of-life distress often manifest as psychological turmoil experienced by patients undergoing advanced illnesses, typically characterised by anxiety, depression, and existential fear concerning death.

The pathophysiology involves complex interactions between psychological well-being, neurobiology, and the stress of facing mortality, leading to profound emotional distress.

Common symptoms include severe anxiety about death, pervasive sadness, feelings of helplessness, and an overall decline in quality of life, often necessitating psychological intervention.

Current Treatments

Standard treatments often include psychotherapy, pharmacological interventions (such as antidepressants and anxiolytics), and palliative care practices aimed at managing symptoms rather than curing the illness.

Psychedelic Effect Matrix

Systematic comparison of compound efficacy and evidence levels for Palliative & End-of-Life Distress.

Compound	Magnitude	Evidence	Consistency
Psilocybin Multiple studies support its significant effect on reducing end-of-life distress in patients.	Large	High	Consistent
LSD Some studies report benefits for anxiety and depression, but results are less conclusive than those for psilocybin.	Medium	Moderate	Inconsistent
MDMA Research shows potential for MDMA in treating anxiety and distress, but further studies are needed.	Medium	Moderate	Inconsistent
Ketamine Demonstrates rapid antidepressant effects, providing symptomatic relief in terminal illness settings.	Medium	Moderate	Consistent

Psilocybin and Palliative & End-of-Life Distress

Psilocybin is believed to facilitate profound psychological experiences that can offer insights and a sense of peace in terminally ill patients. Research indicates that it can significantly alleviate anxiety and existential distress, leading to an enhanced emotional state and a greater acceptance of mortality. Many patients report transformative experiences that contribute to their overall well-being and comfort during palliative care.

View full Psilocybin profile →

Ketamine and Palliative & End-of-Life Distress

Ketamine acts as an NMDA receptor antagonist, offering rapid relief from depressive symptoms, which can be particularly distressing for patients facing end-of-life issues. Its psychedelic properties, combined with its fast-acting nature, make it a candidate for palliative care to improve mood and reduce anxiety, potentially improving patients' overall quality of life.

View full Ketamine profile →

Key Insights

1
Psilocybin-assisted therapy has shown potential in reducing existential distress in terminal cancer patients, with studies indicating significant improvements in psychological well-being.
2
Recent trials highlight that psilocybin can facilitate meaningful therapeutic experiences, leading to lasting positive changes even after a single session.
3
The acceptability of psilocybin treatment appears to be high among patients and healthcare professionals, suggesting a readiness to embrace psychedelic therapies in palliative care settings.

Industrial Landscape

Key industry players include academic research institutions and non-profits such as MAPS (Multidisciplinary Association for Psychedelic Studies) and the Heffter Research Institute, which support psychedelic research and advocate for the therapeutic use of psychedelics in healthcare.

Quick Indicators

PrevalenceApproximately 40% of patients with terminal illnesses report significant distress at the end of life.

Research Footprint

0Trials

0Papers

\"Ongoing clinical evaluations are investigating Palliative & End-of-Life Distress as a primary indication for various psychedelic compounds.\"

Key Organizations

4 Connected

Delix Therapeutics

Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.

MAPS

The description of the stakeholder

Lykos Therapeutics

Longer description of Lykos .. lorem ipsum ..

Leiden University

Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.